--- title: "SLU-PP-915: Dosing & Vendor Prices | BodyHackGuide" url: https://www.bodyhackguide.co/compound/slu-pp-915 description: "SLU-PP-915: dosing protocols, mechanism & side effects. Compare 1 current vendor prices." lang: en --- Skip to content Compare notes on r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Compare notes with other researchers. Join r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Image: SLU-PP-915 molecular structure (https://www.bodyhackguide.co/assets/peptide-structure-placeholder-DUmZBF_j.png) # SLU-PP-915 Metabolic (https://www.bodyhackguide.co/wiki#cat-metabolic)Preclinical Also known as: SLU-PP-915, SLUPP915, pan-ERR agonist SLU-PP-915, ERR agonist 10s SLU-PP-915 is an experimental agonist of the estrogen-related receptors, a family of three orphan nuclear receptors called ERR-alpha, ERR-beta and ERR-gamma that control genes for mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation and the Krebs cycle. It was reported in 2023 by John Walker, Thomas Burris and colleagues as the lead of a new chemical series of pan-ERR agonists (PMID: 37421886). Image: Disguised Alpha logo (https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Lowest price per mg $0.233/mg $139.99 for 600mg at Disguised Alpha Buy at Disguised Alpha: https://disguisedalpha.com/product/slu-pp-915-10mg-capsules/?coupon=reddit Half-life: Not established in humans Route: Oral (rodent studies), Intraperitoneal injection (rodent stud… MW: 341.16 g/mol CAS: 2285432-92-8 Last reviewed: Oct 3, 2026 ## Overview ### At A Glance Mechanism SLU-PP-915 is a pan-agonist of the estrogen-related receptors ERR-alpha, ERR-beta and ERR-gamma, orphan nuclear receptors that drive transcription of genes for mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation and the Krebs cycle and are required for skele… Half-Life Not established in humans; in mice it is orally bioavailable and active by both oral and intraperitoneal routes, unlike its predecessor SLU-PP-332 (PMID: 41421047) Routes Oral (rodent studies) Intraperitoneal injection (rodent studies) Potential Benefits Increased aerobic exercise distance and duration in mice by oral and by injected administration (PMID: 41421047) Induced the acute aerobic exercise response gene Ddit4 in mouse muscle at levels matching or exceeding treadmill running (PMID: 41421047) Increased mitochondrial gene expression further when combined with exercise training in mice (PMID: 41421047) Upregulated the ERR target genes PGC-1alpha, LDHA, DDIT4 and PDK4 in cells and in vivo (PMID: 37421886) In the closely related pan-ERR agonist SLU-PP-332, increased energy expenditure and fatty acid oxidation with reduced fat mass and improved insulin sensitivity in obese mice (PMID: 37739806) ### Overview SLU-PP-915 is an experimental agonist of the estrogen-related receptors, a family of three orphan nuclear receptors called ERR-alpha, ERR-beta and ERR-gamma that control genes for mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation and the Krebs cycle. It was reported in 2023 by John Walker, Thomas Burris and colleagues as the lead of a new chemical series of pan-ERR agonists (PMID: 37421886). It has never been in a human being. No company has taken it into development and no regulator has reviewed it. It is the follow-up to SLU-PP-332, the compound that got press coverage as exercise in a pill. SLU-PP-332 activates all three ERR subtypes and, in mice, increased type IIa oxidative muscle fibers, enhanced running endurance and triggered the gene expression program that a single bout of aerobic exercise produces (PMID: 36988910). In diet-induced obese mice it raised energy expenditure and fatty acid oxidation, reduced fat mass and improved insulin sensitivity (PMID: 37739806). Related pan-ERR agonists improved cardiac fatty acid metabolism and mitochondrial function in heart failure models (PMID: 37961903). SLU-PP-915 exists because SLU-PP-332 has a practical flaw: it is not orally bioavailable, so mice had to be injected. The medicinal chemistry work replaced a phenol or aniline group with a boronic acid, which held potency while improving metabolic stability in liver microsome assays, and the resulting compound raised expression of the ERR target genes PGC-1alpha, LDHA, DDIT4 and PDK4 both in cells and in animals (PMID: 37421886). The 2025 pharmacology paper is the key one. SLU-PP-915 increased aerobic exercise performance in mice, both running distance and duration, to a similar degree as SLU-PP-332 when injected, and held comparable effect when given by mouth after adjusting for systemic exposure. Both compounds strongly induced Ddit4, a gene switched on by acute aerobic exercise, at levels matching or exceeding actual treadmill running in some muscles, and SLU-PP-915 combined with training raised mitochondrial gene expression further than either alone (PMID: 41421047). Everything above is mice. There is no human pharmacokinetic study, no safety study, no dose, and no published record of any person taking it. Anti-doping chemists have already characterized its in vitro metabolites in human liver preparations specifically because they expect it to be misused before it is ever studied properly (PMID: 41588687). Capsules sold as SLU-PP-915 are a laboratory compound that reached a peer-reviewed pharmacology paper in 2025 and skipped every step between that paper and a person swallowing it. ### Potential Research Fields Estrogen-related receptors Exercise mimetics Mitochondrial biogenesis Sports drug testing ## Chemical Information IUPAC Name Not yet available CAS Number 2285432-92-8 Molecular Formula C17H13BFNO3S Molecular Mass 341.16 g/mol Image: SLU-PP-915 molecular structure (https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/142532359/PNG) View on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/142532359 ## Dosing & Protocols ### Unlock the Dosing tab Enter your email to keep reading. It is free, and it opens these tabs on every compound page in this browser. - Route You also get the free peptide cheat sheet by email. Unsubscribe anytime. Have an account? Sign in (https://www.bodyhackguide.co/auth) ## Research ### Unlock the research summary - A summary of the key research - Safety and side effects - A link to the PubMed results ## Interactions ### Contraindications None can be stated from evidence, because no human has been studied. Mechanism-based caution applies broadly: ERR agonism alters mitochondrial and metabolic gene transcription across muscle, heart, kidney and liver (PMID: 37961903; PMID: 37717940), and no organ safety margin has been established in any species at doses relevant to human use. No reproductive, developmental, hepatic or renal safety data exist. Research Disclaimer This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds. Best Price $139.99 Best $/mg $0.2333 Vendors 1 Listings 1 capsule Form Sort | Vendor | Product | Form | Qty | Price | $/mg | Coupon | | | --- | --- | --- | --- | --- | --- | --- | --- | | Image: Disguised Alpha logo (https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Disguised Alpha (https://www.bodyhackguide.co/vendors/disguised-alpha) 50: https://www.bodyhackguide.co/vendor-trust-scorecard 🇺🇸 US 🇪🇺 EU 🇬🇧 UK | SLU-PP-915 10 mg capsules (60) | capsule | 60 capsules (10 mg) ● In Stock | $139.99 BEST | $0.233 | — | Buy: https://disguisedalpha.com/product/slu-pp-915-10mg-capsules/?coupon=reddit | ### Sign in to leave a review Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with SLU-PP-915. Current low $139.99 current listings 7-day low — not enough history yet 30-day low — not enough history yet 30-day change — not enough history yet Tracking since Sep 7, 2026 · 1 data point ### Vendors Selling SLU-PP-915 #### Disguised Alpha 1 listing · from $139.99 https://www.bodyhackguide.co/vendors/disguised-alpha How we score these vendors Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. View Scorecard (https://www.bodyhackguide.co/vendors/scorecard) ### Related Compounds View All (https://www.bodyhackguide.co/wiki) ### AICAR (acadesine) Metabolic Phase 3 AICAR is a nucleoside analog of adenosine. t½ Intact acadesine was measurable in plasma for only about 2 hours after a short intravenous infusion in four healthy men, with total plasma clearance of 2.2 L/h/kg and negligible protein binding; radiolabeled drug-derived material had an apparent terminal half-life of about one week, reflecting metabolites rather than parent compound (PMID: 8227467) Preclinical View Profile https://www.bodyhackguide.co/compound/aicar ### Amlexanox Metabolic FDA Approved Amlexanox is an old anti-inflammatory drug with a second life. t½ Not established in published human pharmacokinetic studies for the oral capsule form; a validated plasma assay has been used for preclinical pharmacokinetics in rats (PMID: 34842293) Preclinical View Profile https://www.bodyhackguide.co/compound/amlexanox ### Berberine Metabolic Preclinical Berberine is an isoquinoline alkaloid — a naturally occurring plant secondary metabolite with a characteristic yellow color — extracted from the roots, rhizomes, stems, and bark of several plant genera including Berberis (barberry, Oregon grape), Coptis (goldthread), Hydrastis (goldenseal), Phellodendron (Amur cork tree), and Tinospora (guduchi). Preclinical View Profile https://www.bodyhackguide.co/compound/berberine ### Cardarine (GW501516) Metabolic Discontinued Cardarine is the market name for GW501516, a synthetic agonist of the nuclear receptor PPAR-delta developed by GlaxoSmithKline as a treatment for low HDL cholesterol and the lipid problems that travel with metabolic syndrome. t½ Not reported in the published human trials; the phase 1 and phase 2 studies described lipid outcomes over two to twelve weeks of oral dosing without publishing a terminal half-life (PMID: 17110604; PMID: 22814748) Preclinical View Profile https://www.bodyhackguide.co/compound/cardarine ### Metformin Metabolic Preclinical Metformin is a biguanide-class oral antihyperglycemic medication that has been in continuous clinical use since 1957 (in France under the brand name Glucophage) and is now the most-prescribed diabetes medication worldwide with over 150 million prescriptions annually. Preclinical View Profile https://www.bodyhackguide.co/compound/metformin ### Sobetirome (GC-1) Metabolic Discontinued Sobetirome, also called GC-1 and later QRX-431, is a synthetic analog of thyroid hormone made in Thomas Scanlan laboratory and first described in 1998 as a high-affinity, subtype-selective agonist for the thyroid hormone receptor (PMID: 9653548). t½ Not established in humans; no peer-reviewed human pharmacokinetic study has been published, and the phase 1 program results were not reported in the peer-reviewed literature (PMID: 19002578) Preclinical View Profile https://www.bodyhackguide.co/compound/sobetirome View Full Dosage Guide → Protocols, calculator & safety for SLU-PP-915 https://www.bodyhackguide.co/guides/dosage/slu-pp-915 ### Lowest Price per mg Disguised Alpha $139.99($0.233/mg) 1 vendor · 1 listing ### Research Score 30 0 PubMed results ### Quality Indicators Data Completeness 63% Description Mechanism of Action Chemical Data Dosing Protocols Safety Profile PubMed Results Interactions Vendor Listings ### Quick Facts Half-Life Molecular Weight 341.16 g/mol Administration Oral (rodent studies), Intraperitoneal injection (rodent studies) CAS Number 2285432-92-8 Trial Phase Preclinical 0 Research Disclaimer This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use. ## Frequently Asked Questions What is SLU-PP-915 used for in research? SLU-PP-915 is an experimental agonist of the estrogen-related receptors, a family of three orphan nuclear receptors called ERR-alpha, ERR-beta and ERR-gamma that control genes for mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation and the Krebs cycle. It was reported in 2023 by John Walker, Thomas Burris and colleagues as the lead of a new chemical series of pan-ERR agonists (PMID: 37421886). It has never been in a human being. No company has taken it into development and no regulator has reviewed it. It is the follow-up to SLU-PP-332, the compound that got press coverage as exercise in a pill. SLU-PP-332 activates all three ERR subtypes and, in mice, increased type IIa oxidative muscle fibers, enhanced running endurance and triggered the gene expression program that a single bout of aerobic exercise produces (PMID: 36988910). In diet-induced obese mice it raised energy expenditure and fatty acid oxidation, reduced fat mass and improved insulin sensitivity (PMID: 37739806). Related pan-ERR agonists improved cardiac fatty acid metabolism and mitochondrial function in heart failure models (PMID: 37961903). SLU-PP-915 exists because SLU-PP-332 has a practical flaw: it is not orally bioavailable, so mice had to be injected. The medicinal chemistry work replaced a phenol or aniline group with a boronic acid, which held potency while improving metabolic stability in liver microsome assays, and the resulting compound raised expression of the ERR target genes PGC-1alpha, LDHA, DDIT4 and PDK4 both in cells and in animals (PMID: 37421886). The 2025 pharmacology paper is the key one. SLU-PP-915 increased aerobic exercise performance in mice, both running distance and duration, to a similar degree as SLU-PP-332 when injected, and held comparable effect when given by mouth after adjusting for systemic exposure. Both compounds strongly induced Ddit4, a gene switched on by acute aerobic exercise, at levels matching or exceeding actual treadmill running in some muscles, and SLU-PP-915 combined with training raised mitochondrial gene expression further than either alone (PMID: 41421047). Everything above is mice. There is no human pharmacokinetic study, no safety study, no dose, and no published record of any person taking it. Anti-doping chemists have already characterized its in vitro metabolites in human liver preparations specifically because they expect it to be misused before it is ever studied properly (PMID: 41588687). Capsules sold as SLU-PP-915 are a laboratory compound that reached a peer-reviewed pharmacology paper in 2025 and skipped every step between that paper and a person swallowing it. What forms does SLU-PP-915 come in? SLU-PP-915 is available in capsule form. How much does SLU-PP-915 cost? Prices start at $139.99 across 1 vendor. How do I compare SLU-PP-915 vendors? Compare prices, payment methods, shipping, and COA scores across 1 vendor. ## Research Tools ### Peptide Calculator Reconstitution & syringe units https://www.bodyhackguide.co/tools/reconstitution ### Reconstitution Guide How to mix, step by step https://www.bodyhackguide.co/guides/how-to-reconstitute-peptides ### Nasal Spray Calc mL per actuation https://www.bodyhackguide.co/tools/intranasal ### Half-Life Visualizer Decay curves https://www.bodyhackguide.co/tools/halflife ## Related Compounds ### AICAR (acadesine) Metabolic Phase 3 ### Amlexanox Metabolic FDA Approved ### Berberine Metabolic Preclinical ### Cardarine (GW501516) Metabolic Discontinued ### Metformin Metabolic Preclinical ### Sobetirome (GC-1) Metabolic Discontinued Free 2026 Peptide Cheat Sheet (PDF) 38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers. Download Free (https://www.bodyhackguide.co/guides/peptide-cheat-sheet-download) ### Need bloodwork before starting? Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount. Image: BodyHackGuide (https://www.bodyhackguide.co/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub: compound pricing, brain health protocols, dosing tools, and vendor reviews. support@bodyhackguide.co Join our Discord: https://discord.gg/Mhq5UdRYBA r/BodyHackGuide on Reddit: https://reddit.com/r/BodyHackGuide #### Explore - Compare prices: https://www.bodyhackguide.co/compare - Vendors: https://www.bodyhackguide.co/vendors - Deals: https://www.bodyhackguide.co/deals - Coupons: https://www.bodyhackguide.co/coupons - Nootropics: https://www.bodyhackguide.co/nootropics - Brain health: https://www.bodyhackguide.co/brain-health - Blog: https://www.bodyhackguide.co/blog - Guides: https://www.bodyhackguide.co/guides #### Tools - Reconstitution: https://www.bodyhackguide.co/tools/reconstitution - Half-life visualizer: https://www.bodyhackguide.co/tools/halflife - COA reader: https://www.bodyhackguide.co/tools/coa - Cost calculator: https://www.bodyhackguide.co/tools/cost-calculator - Stack builder: https://www.bodyhackguide.co/stack-builder - All tools: https://www.bodyhackguide.co/tools #### Trust & vendors - Vendor directory: https://www.bodyhackguide.co/vendors - Trust scorecard: https://www.bodyhackguide.co/vendors/scorecard - Vendor trust badge: https://www.bodyhackguide.co/vendors/get-vetted - Scoring methodology: https://www.bodyhackguide.co/vendors/methodology - Peptide cheat sheet: https://www.bodyhackguide.co/guides/peptide-cheat-sheet-download #### Company - About: https://www.bodyhackguide.co/about - Affiliate disclosure: https://www.bodyhackguide.co/affiliate-disclosure - Editorial standards: https://www.bodyhackguide.co/editorial-standards - Creators: https://www.bodyhackguide.co/creators - Coaches: https://www.bodyhackguide.co/coaches - 1-on-1 coaching: https://www.bodyhackguide.co/coaching - Privacy: https://www.bodyhackguide.co/privacy - Terms: https://www.bodyhackguide.co/terms - Full site directory: https://www.bodyhackguide.co/site-directory **Affiliate Disclosure:** We rank every vendor on the same public, reproducible methodology (https://www.bodyhackguide.co/vendors/methodology), and we earn a commission from purchases made through some of our links at no extra cost to you. Full details in our affiliate disclosure (https://www.bodyhackguide.co/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell or ship any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · Terms (https://www.bodyhackguide.co/terms) · Privacy (https://www.bodyhackguide.co/privacy) ## Structured data ```json [ { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Compounds", "item": "https://www.bodyhackguide.co/compare" }, { "@type": "ListItem", "position": 3, "name": "SLU-PP-915" } ] }, { "@context": "https://schema.org", "@type": "Product", "name": "SLU-PP-915", "description": "SLU-PP-915 is an experimental agonist of the estrogen-related receptors, a family of three orphan nuclear receptors called ERR-alpha, ERR-beta and ERR-gamma that control genes for mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation and the Krebs cycle. It was reported in 2023 by John Walker, Thomas Burris and colleagues as the lead of a new chemical series of pan-ERR agonists (PMID: 37421886). It has never been in a human being. No company has taken it into development and no regulator has reviewed it. It is the follow-up to SLU-PP-332, the compound that got press coverage as exercise in a pill. SLU-PP-332 activates all three ERR subtypes and, in mice, increased type IIa oxidative muscle fibers, enhanced running endurance and triggered the gene expression program that a single bout of aerobic exercise produces (PMID: 36988910). In diet-induced obese mice it raised energy expenditure and fatty acid oxidation, reduced fat mass and improved insulin sensitivity (PMID: 37739806). Related pan-ERR agonists improved cardiac fatty acid metabolism and mitochondrial function in heart failure models (PMID: 37961903). SLU-PP-915 exists because SLU-PP-332 has a practical flaw: it is not orally bioavailable, so mice had to be injected. The medicinal chemistry work replaced a phenol or aniline group with a boronic acid, which held potency while improving metabolic stability in liver microsome assays, and the resulting compound raised expression of the ERR target genes PGC-1alpha, LDHA, DDIT4 and PDK4 both in cells and in animals (PMID: 37421886). The 2025 pharmacology paper is the key one. SLU-PP-915 increased aerobic exercise performance in mice, both running distance and duration, to a similar degree as SLU-PP-332 when injected, and held comparable effect when given by mouth after adjusting for systemic exposure. Both compounds strongly induced Ddit4, a gene switched on by acute aerobic exercise, at levels matching or exceeding actual treadmill running in some muscles, and SLU-PP-915 combined with training raised mitochondrial gene expression further than either alone (PMID: 41421047). Everything above is mice. There is no human pharmacokinetic study, no safety study, no dose, and no published record of any person taking it. Anti-doping chemists have already characterized its in vitro metabolites in human liver preparations specifically because they expect it to be misused before it is ever studied properly (PMID: 41588687). Capsules sold as SLU-PP-915 are a laboratory compound that reached a peer-reviewed pharmacology paper in 2025 and skipped every step between that paper and a person swallowing it.", "url": "https://www.bodyhackguide.co/compound/slu-pp-915", "image": "https://www.bodyhackguide.co/og-image.png", "brand": { "@type": "Brand", "name": "Research Compound" }, "offers": { "@type": "AggregateOffer", "lowPrice": "139.99", "highPrice": "139.99", "priceCurrency": "USD", "offerCount": "1", "availability": "https://schema.org/InStock", "offers": [ { "@type": "Offer", "price": "139.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://disguisedalpha.com/product/slu-pp-915-10mg-capsules/?coupon=reddit", "seller": { "@type": "Organization", "name": "Disguised Alpha", "url": "https://disguisedalpha.com/?coupon=reddit" }, "name": "SLU-PP-915 600mg capsule" } ] } }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "SLU-PP-915", "description": "SLU-PP-915 is an experimental agonist of the estrogen-related receptors, a family of three orphan nuclear receptors called ERR-alpha, ERR-beta and ERR-gamma that control genes for mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation and the Krebs cycle. It was reported in 2023 by John Walker, Thomas Burris and colleagues as the lead of a new chemical series of pan-ERR agonists (PMID: 37421886). It has never been in a human being. No company has taken it into development and no regulator has reviewed it. It is the follow-up to SLU-PP-332, the compound that got press coverage as exercise in a pill. SLU-PP-332 activates all three ERR subtypes and, in mice, increased type IIa oxidative muscle fibers, enhanced running endurance and triggered the gene expression program that a single bout of aerobic exercise produces (PMID: 36988910). In diet-induced obese mice it raised energy expenditure and fatty acid oxidation, reduced fat mass and improved insulin sensitivity (PMID: 37739806). Related pan-ERR agonists improved cardiac fatty acid metabolism and mitochondrial function in heart failure models (PMID: 37961903). SLU-PP-915 exists because SLU-PP-332 has a practical flaw: it is not orally bioavailable, so mice had to be injected. The medicinal chemistry work replaced a phenol or aniline group with a boronic acid, which held potency while improving metabolic stability in liver microsome assays, and the resulting compound raised expression of the ERR target genes PGC-1alpha, LDHA, DDIT4 and PDK4 both in cells and in animals (PMID: 37421886). The 2025 pharmacology paper is the key one. SLU-PP-915 increased aerobic exercise performance in mice, both running distance and duration, to a similar degree as SLU-PP-332 when injected, and held comparable effect when given by mouth after adjusting for systemic exposure. Both compounds strongly induced Ddit4, a gene switched on by acute aerobic exercise, at levels matching or exceeding actual treadmill running in some muscles, and SLU-PP-915 combined with training raised mitochondrial gene expression further than either alone (PMID: 41421047). Everything above is mice. There is no human pharmacokinetic study, no safety study, no dose, and no published record of any person taking it. Anti-doping chemists have already characterized its in vitro metabolites in human liver preparations specifically because they expect it to be misused before it is ever studied properly (PMID: 41588687). Capsules sold as SLU-PP-915 are a laboratory compound that reached a peer-reviewed pharmacology paper in 2025 and skipped every step between that paper and a person swallowing it.", "lastReviewed": "2026-10-03T14:37:08.433Z", "url": "https://www.bodyhackguide.co/compound/slu-pp-915", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" }, "mainContentOfPage": { "@type": "WebPageElement", "cssSelector": "main" }, "about": { "@type": "Drug", "name": "SLU-PP-915", "alternateName": [ "SLU-PP-915", "SLUPP915", "pan-ERR agonist SLU-PP-915", "ERR agonist 10s" ], "description": "SLU-PP-915 is an experimental agonist of the estrogen-related receptors, a family of three orphan nuclear receptors called ERR-alpha, ERR-beta and ERR-gamma that control genes for mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation and the Krebs cycle. It was reported in 2023 by John Walker, Thomas Burris and colleagues as the lead of a new chemical series of pan-ERR agonists (PMID: 37421886). It has never been in a human being. No company has taken it into development and no regulator has reviewed it. It is the follow-up to SLU-PP-332, the compound that got press coverage as exercise in a pill. SLU-PP-332 activates all three ERR subtypes and, in mice, increased type IIa oxidative muscle fibers, enhanced running endurance and triggered the gene expression program that a single bout of aerobic exercise produces (PMID: 36988910). In diet-induced obese mice it raised energy expenditure and fatty acid oxidation, reduced fat mass and improved insulin sensitivity (PMID: 37739806). Related pan-ERR agonists improved cardiac fatty acid metabolism and mitochondrial function in heart failure models (PMID: 37961903). SLU-PP-915 exists because SLU-PP-332 has a practical flaw: it is not orally bioavailable, so mice had to be injected. The medicinal chemistry work replaced a phenol or aniline group with a boronic acid, which held potency while improving metabolic stability in liver microsome assays, and the resulting compound raised expression of the ERR target genes PGC-1alpha, LDHA, DDIT4 and PDK4 both in cells and in animals (PMID: 37421886). The 2025 pharmacology paper is the key one. SLU-PP-915 increased aerobic exercise performance in mice, both running distance and duration, to a similar degree as SLU-PP-332 when injected, and held comparable effect when given by mouth after adjusting for systemic exposure. Both compounds strongly induced Ddit4, a gene switched on by acute aerobic exercise, at levels matching or exceeding actual treadmill running in some muscles, and SLU-PP-915 combined with training raised mitochondrial gene expression further than either alone (PMID: 41421047). Everything above is mice. There is no human pharmacokinetic study, no safety study, no dose, and no published record of any person taking it. Anti-doping chemists have already characterized its in vitro metabolites in human liver preparations specifically because they expect it to be misused before it is ever studied properly (PMID: 41588687). Capsules sold as SLU-PP-915 are a laboratory compound that reached a peer-reviewed pharmacology paper in 2025 and skipped every step between that paper and a person swallowing it.", "activeIngredient": "SLU-PP-915", "administrationRoute": "Oral (rodent studies), Intraperitoneal injection (rodent studies)", "mechanismOfAction": "SLU-PP-915 is a pan-agonist of the estrogen-related receptors ERR-alpha, ERR-beta and ERR-gamma, orphan nuclear receptors that drive transcription of genes for mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation and the Krebs cycle and are required for skeletal muscle adaptation to aerobic exercise. It came from a 2,5-disubstituted thiophene series designed around ERR-gamma, in which a boronic acid group replaced phenol or aniline to improve microsomal stability while keeping potency across all three subtypes; the compound upregulates the ERR target genes PGC-1alpha, LDHA, DDIT4 and PDK4 in vitro and in vivo (PMID: 37421886). In mice it induces Ddit4, an acute aerobic exercise response gene, at levels comparable with treadmill running and increases running distance and duration by oral and intraperitoneal routes (PMID: 41421047).", "dosageForm": "capsule", "legalStatus": "Not approved for human use (research chemical)", "warning": "For research purposes only. Not for human consumption." } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is SLU-PP-915 used for in research?", "acceptedAnswer": { "@type": "Answer", "text": "SLU-PP-915 is an experimental agonist of the estrogen-related receptors, a family of three orphan nuclear receptors called ERR-alpha, ERR-beta and ERR-gamma that control genes for mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation and the Krebs cycle. It was reported in 2023 by John Walker, Thomas Burris and colleagues as the lead of a new chemical series of pan-ERR agonists (PMID: 37421886). It has never been in a human being. No company has taken it into development and no regulator has reviewed it. It is the follow-up to SLU-PP-332, the compound that got press coverage as exercise in a pill. SLU-PP-332 activates all three ERR subtypes and, in mice, increased type IIa oxidative muscle fibers, enhanced running endurance and triggered the gene expression program that a single bout of aerobic exercise produces (PMID: 36988910). In diet-induced obese mice it raised energy expenditure and fatty acid oxidation, reduced fat mass and improved insulin sensitivity (PMID: 37739806). Related pan-ERR agonists improved cardiac fatty acid metabolism and mitochondrial function in heart failure models (PMID: 37961903). SLU-PP-915 exists because SLU-PP-332 has a practical flaw: it is not orally bioavailable, so mice had to be injected. The medicinal chemistry work replaced a phenol or aniline group with a boronic acid, which held potency while improving metabolic stability in liver microsome assays, and the resulting compound raised expression of the ERR target genes PGC-1alpha, LDHA, DDIT4 and PDK4 both in cells and in animals (PMID: 37421886). The 2025 pharmacology paper is the key one. SLU-PP-915 increased aerobic exercise performance in mice, both running distance and duration, to a similar degree as SLU-PP-332 when injected, and held comparable effect when given by mouth after adjusting for systemic exposure. Both compounds strongly induced Ddit4, a gene switched on by acute aerobic exercise, at levels matching or exceeding actual treadmill running in some muscles, and SLU-PP-915 combined with training raised mitochondrial gene expression further than either alone (PMID: 41421047). Everything above is mice. There is no human pharmacokinetic study, no safety study, no dose, and no published record of any person taking it. Anti-doping chemists have already characterized its in vitro metabolites in human liver preparations specifically because they expect it to be misused before it is ever studied properly (PMID: 41588687). Capsules sold as SLU-PP-915 are a laboratory compound that reached a peer-reviewed pharmacology paper in 2025 and skipped every step between that paper and a person swallowing it." } }, { "@type": "Question", "name": "What forms does SLU-PP-915 come in?", "acceptedAnswer": { "@type": "Answer", "text": "SLU-PP-915 is available in capsule form." } }, { "@type": "Question", "name": "How much does SLU-PP-915 cost?", "acceptedAnswer": { "@type": "Answer", "text": "Prices start at $139.99 across 1 vendor." } }, { "@type": "Question", "name": "How do I compare SLU-PP-915 vendors?", "acceptedAnswer": { "@type": "Answer", "text": "Compare prices, payment methods, shipping, and COA scores across 1 vendor." } } ] }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, vendor price comparisons, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. We earn a commission on purchases through some of our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" } ] ```